US-based medical technology company Tempus AI has announced the expansion of its generative AI clinical assistant, Tempus One, by integrating it directly into electronic health record (EHR) systems.
The integration aims to enhance clinical care processes by providing physicians, particularly in oncology, with robust support in treatment decisions through AI-enabled insights.
It leverages Tempus AI’s extensive network with healthcare providers across the US, helping physicians streamline complex treatment decisions and save time on administrative tasks.
The platform’s architecture captures real-time clinical, molecular, and imaging data from millions of patients, making this data accessible and actionable for clinicians.
The updated Tempus One has integrated the American Society of Clinical Oncology (ASCO) guideline, allowing oncologists to deliver personalised patient care.
Physicians can now easily access ASCO’s guidelines to inform their clinical decisions with the latest evidence-based treatment and care recommendations.
Tempus One also introduces new features to help improve clinical workflows, including pre-appointment preparation by summarising patient history and treatment journeys.
During appointments, it transcribes conversations, takes intelligent notes, and highlights key information, allowing physicians to focus on patient care.
Post-appointment, it helps in documentation, treatment planning, and clinical trial matching.
In addition, Tempus has developed the Agent Builder GenAI tool, which has been used internally to create over one thousand AI agents.
The tool is now available to select partner providers, enabling them to develop custom GenAI solutions tailored to their specific needs.
Tempus chief operating officer Ryan Fukushima said: “As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams.
“This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.”
In a separate development, Tempus AI has launched the Fuses programme, which aims to harness its proprietary dataset to generate valuable insights for patient care and research.
The programme combines data and machine learning capabilities to develop an AI-enabled diagnostic platform, providing physicians with a comprehensive suite of algorithmic tests.
Fuses will advance Tempus’ testing portfolio by expanding its suite of AI-enabled diagnostics, and its insights will be developed into clinically validated algorithmic diagnostics.
The foundational model behind Fuses is designed to learn generalisable rules for determining prognosis and drug benefit in real-world practice.
It aims to enhance researchers’ understanding of clinical trial failures, identify new indications, optimise trial design, and uncover combination therapies.
The model may also uncover mechanisms of drug response and resistance, inspiring a new generation of companion diagnostics and therapeutic research.
Tempus founder and CEO Eric Lefkofsky said: “We have spent the last ten years building, scaling, and curating one of the most comprehensive datasets in our industry, and now we are well positioned to develop the world’s largest diagnostic model, designed to answer critical, unsolved questions and make our diagnostics smarter and more personalised.
“We are on the brink of delivering tangible, transformative change in matching the right therapies to the right patients, making personalised care a reality for millions.”
